The Latest in Ovarian Cancer Treatment and Research

0

Although ovarian cancer is often difficult to treat, research continues to yield results that are improving outcomes and quality of life for many patients.

Ursula Matulonis, MD; Susana Campos, MD, MPH; and Panos Konstantinopoulos, MD, PhD

Ursula Matulonis, MD; Susana Campos, MD, MPH; and Panos Konstantinopoulos, MD, PhD

“Ovarian cancer research and treatment is exciting today because there are so many resources available and we are no longer committed to just the standard chemotherapy,” says Susana Campos, MD, MPH, a gynecologic oncologist with the Susan F. Smith Center for Women’s Cancers at Dana-Farber. “People can really have fruitful lives even if they are living with ovarian cancer.”

Campos recently joined fellow gynecologic oncologist Panos Konstantinopoulos, MD, PhD, for a live video webchat led by Ursula Matulonis, MD, medical director for the Gynecologic Oncology Program at the Susan F. Smith Center.

The chat, which included questions submitted by patients and viewers, covered the latest research developments and treatment options for ovarian cancer, including advances in immunotherapy, PARP inhibitors and genetic profiling.

“I’m very excited about the different combinations of therapies that we are exploring,” Matulonis says. “It only makes sense that we combine these therapies to really tackle the different, innate problems in ovarian cancer.”

“We live in an exciting time in ovarian cancer research with a lot of novel drugs that are being developed,” Konstantinopoulos says. “I think there is a bright future for our patients who fight this difficult disease.”

View a recording of the webchat below:

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dr. Matthew Davids explores combining ibrutinib with FCR (iFCR) for younger patients with previously-untreated chro… https://t.co/wzVpo47tSa
Dana-Farber @danafarber
“We’re changing the way people are cared for, through #precisionmedicine, precision care, and a total team approach… https://t.co/RnZXsH2rW8
Dana-Farber @danafarber
Cell-weighing method could help doctors choose #cancer drugs: https://t.co/YesjtyxIvR via @MIT https://t.co/0F7wsZSuLJ

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.